Core Insights - Galectin Therapeutics, Inc. reported significant advancements in the belapectin development program, particularly in addressing MASH cirrhosis and portal hypertension, with promising data from the NAVIGATE dataset [2][3] Financial Highlights - The company secured a $10 million line of credit, extending its cash runway through April 2027 [3] - As of December 31, 2025, Galectin had $17.7 million in unrestricted cash and cash equivalents, alongside the $10 million line of credit [10] - Research and development expenses decreased to $14.3 million in 2025 from $36.6 million in 2024, primarily due to the conclusion of the NAVIGATE trial [10] - The net loss applicable to common stockholders for 2025 was $31.0 million, or ($0.48) per share, down from a net loss of $47.2 million, or ($0.76) per share, in 2024 [10][13] Belapectin Program Highlights - Belapectin targets galectin-3, a protein involved in fibrosis and inflammation related to MASH and portal hypertension [4] - The NAVIGATE Phase 2b/3 trial showed a 43.2% reduction in varices incidence at 18 months in the intent-to-treat population and a 49.3% reduction in the per-protocol population [5] - In U.S. patients within the per-protocol population, belapectin 2 mg/kg reduced varices incidence by 68.1% compared to placebo [5] - Safety results indicated no drug-related serious adverse events, with similar rates of treatment-emergent adverse events across groups [5] Biomarker Insights - Additional analyses from the NAVIGATE trial demonstrated consistent signals across non-invasive markers of fibrosis and liver stiffness, supporting belapectin's antifibrotic activity [6][10] - The company plans to present new analyses at the EASL Congress in May 2026, including findings on reduced varices and risk reduction in portal hypertension [10]

Core Viewpoint - Galectin Therapeutics Inc. has appointed Dr. Henry Brem as an independent director to its Board of Directors, enhancing its leadership with expertise in clinical development and translational medicine [1][3]. Company Overview - Galectin Therapeutics focuses on developing novel therapies for chronic liver disease and cancer, with its lead drug belapectin targeting galectin-3 to treat metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis [5]. - Belapectin has received Fast Track designation from the U.S. FDA, indicating its potential as a significant therapeutic option for a pressing medical need [5]. Leadership and Expertise - Dr. Brem is recognized for his contributions to neurosurgical oncology and has a strong background in clinical development, which will support Galectin's strategic priorities [2][3]. - His experience includes leading complex clinical programs and advancing novel therapeutic platforms through regulatory approval, which is expected to be invaluable for the advancement of belapectin [3][4]. Strategic Goals - The appointment of Dr. Brem is part of Galectin's strategy to strengthen its Board with leaders who possess deep scientific and clinical expertise, aligning with the company's upcoming milestones [4]. - The company aims to leverage its scientific and development expertise to achieve cost-effective and efficient drug development, particularly in finding suitable partners for additional clinical programs [5].

Core Viewpoint - The event focuses on discussing belapectin as a treatment for MASH cirrhosis with portal hypertension, highlighting its potential to address a significant unmet medical need in this area [2][4]. Group 1: Event Overview - The virtual KOL event is hosted by LifeSci Consulting, with Michael Cozart as the moderator [1]. - Key opinion leaders participating include Dr. Naga Chalasani and Dr. Naim Alkhouri, who bring expertise in gastroenterology and hepatology [3]. Group 2: Medical Insights - Khurram Jamil, Galectin's Chief Medical Officer, will provide an overview of MASH cirrhosis with portal hypertension and discuss belapectin's capabilities [4].

Summary of Galectin Therapeutics KOL Event on Belapectin for MASH Cirrhosis Company and Industry Overview - **Company**: Galectin Therapeutics (NasdaqCM: GALT) - **Industry**: Treatment of MASH (Metabolic Associated Steatotic Hepatitis) cirrhosis with portal hypertension Core Points and Arguments - **Rising Prevalence of MASH Cirrhosis**: The prevalence of MASH cirrhosis is increasing in the U.S., primarily due to rising obesity and type 2 diabetes rates. Over 5 million individuals are estimated to be living with MASH cirrhosis, while fewer than 12,000 liver transplants were performed last year, highlighting a significant unmet medical need [4][5] - **Belapectin's Mechanism**: Belapectin is a complex carbohydrate that targets Galectin-3, a protein linked to fibrosis. It has shown potential in reducing fibrosis and inflammation in preclinical studies, making it a novel treatment option for MASH cirrhosis and portal hypertension [5] - **Market Opportunity**: The economic burden of MASH cirrhosis, combined with the lack of FDA-approved pharmacological therapies, presents a multi-billion dollar market opportunity for belapectin [6] - **Clinical Trial Results**: The NAVIGATE trial, a pivotal study, demonstrated that belapectin significantly reduced the development of new esophageal varices in patients with MASH cirrhosis and portal hypertension. The 2 mg/kg dose showed a 50% reduction in new varices compared to placebo [16][31] - **Safety Profile**: The safety profile of belapectin was reported as excellent, with no significant adverse events or drug-induced liver injury observed [17][31] Additional Important Content - **Current Treatment Landscape**: There are currently no approved treatments for NASH cirrhosis. Management primarily involves lifestyle interventions and monitoring for complications [10] - **Biomarker Insights**: The trial included various biomarkers to assess liver stiffness and fibrosis, showing that belapectin treatment led to a reduction in liver stiffness and other fibrosis markers compared to placebo [22][30] - **Regulatory Discussions**: Galectin Therapeutics is focused on advancing discussions with regulatory agencies and identifying partners to further develop the belapectin program [33] - **Non-Invasive Diagnosis**: There is a shift away from liver biopsies for diagnosing cirrhosis, with reliance on non-invasive modalities like VCTE and ELF scores [38][40] This summary encapsulates the key points discussed during the Galectin Therapeutics KOL event, emphasizing the potential of belapectin in addressing the unmet needs of patients with MASH cirrhosis and portal hypertension.

Core Insights - Galectin Therapeutics Inc. is hosting a virtual key opinion leader (KOL) event on March 10, 2026, to discuss the treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension [1][2] - The event will present updated results from the NAVIGATE Phase 3 clinical trial of belapectin, which shows potential as the first treatment for MASH cirrhosis, addressing a significant unmet medical need [2] Company Overview - Galectin Therapeutics focuses on developing therapies for chronic liver disease and cancer, with its lead drug belapectin targeting galectin-3, a protein involved in MASH and fibrosis [7] - Belapectin has received Fast Track designation from the U.S. FDA and is positioned to address the pressing medical need for treatments in liver cirrhosis [7] Clinical Development - The NAVIGATE Phase 3 trial results reinforce the antifibrotic and disease-modifying potential of belapectin, which may be the first approved therapy for preventing or treating varices in MASH cirrhosis [2] - The company aims to leverage its scientific expertise and external relationships to achieve efficient drug development [7]

Core Viewpoint - Galectin Therapeutics Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price after an FDA communication regarding its drug development program [1][3]. Group 1: Company Developments - On December 19, 2025, Galectin Therapeutics announced that the FDA provided a written response to its Type C meeting request concerning the development of belapectin, an investigational galectin-3 inhibitor [2]. - The FDA's response converted the company's request for an in-person or teleconference meeting into a written format, indicating that while there is alignment on the proposed patient population for a registration trial, key aspects of the trial design remain unresolved [2]. Group 2: Market Reaction - Following the FDA's communication, Galectin's stock price experienced a decline of over 28% on the same day [3].

Core Viewpoint - Levi & Korsinsky has initiated an investigation into Galectin Therapeutics Inc. for potential violations of federal securities laws following a significant drop in the company's stock price after FDA communications regarding its drug development program [1][3]. Group 1: Company Developments - Galectin Therapeutics announced on December 19, 2025, that the FDA provided a written response to its Type C meeting request concerning the development of belapectin, an investigational galectin-3 inhibitor [2]. - The FDA's response converted the company's request for an in-person or teleconference meeting into a written format, indicating that while there is alignment on the proposed patient population for a registration trial, key aspects of the trial design remain unresolved [2]. Group 2: Market Reaction - Following the FDA's communication, Galectin's stock price experienced a decline of over 28% on December 19, 2025, reflecting investor concerns regarding the unresolved aspects of the clinical trial design [3]. Group 3: Legal Context - Levi & Korsinsky, a recognized securities litigation firm, has a history of securing significant recoveries for shareholders and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Galectin Therapeutics Inc. and its officers or directors [1] Group 1: Company Developments - On December 19, 2025, Galectin announced that the FDA provided a written response to its Type C meeting request regarding the development program for belapectin, an investigational galectin-3 inhibitor [3] - The FDA's response converted the initial request for an in-person or teleconference meeting to a written format, indicating that key aspects of the trial design remain unresolved despite alignment on the proposed patient population for a registration trial [3] Group 2: Market Reaction - Following the news of the FDA's response, Galectin's stock price fell by $1.78 per share, or 28.9%, closing at $4.38 per share on December 19, 2025 [4]

Core Viewpoint - The Schall Law Firm is investigating Galectin Therapeutics Inc. for potential violations of securities laws related to misleading statements and failure to disclose important information to investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Galectin issued false or misleading statements regarding its development program for belapectin, an investigational galectin-3 inhibitor [2]. - On December 19, 2025, Galectin announced that the FDA provided a written response to its Type C meeting request, which was initially sought as an in-person or teleconference meeting [2]. - Following the announcement, Galectin's shares experienced a significant decline of 28.9% on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who suffered losses are encouraged to contact the firm for a free discussion of their rights [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Galectin Therapeutics Inc. and its officers and directors [1] Group 1: Company Developments - On December 19, 2025, Galectin announced that the FDA provided a written response to its Type C meeting request regarding the development program for belapectin, an investigational galectin-3 inhibitor [3] - The FDA's response converted the initial request for an in-person or teleconference meeting to a written format, indicating that key aspects of the trial design remain unresolved despite alignment on the proposed patient population for a registration trial [3] Group 2: Market Reaction - Following the news of the FDA's response, Galectin's stock price fell by $1.78 per share, or 28.9%, closing at $4.38 per share on December 19, 2025 [4]